Important pharmacy news and late-breaking industry information updated daily.
Public health officials and vaccine manufacturers are making millions of extra influenza vaccine doses in anticipation of a simultaneous assault of coronavirus and seasonal influenza this winter.
Top federal health officials warned Tuesday of a "disturbing surge" of infections in some parts of the country, as Americans ignore social distancing guidelines and states reopen without adequate plans for testing and tracing the contacts of those who get sick.
A bipartisan group of U.S. lawmakers introduced a pair of bills Monday that would prohibit drug makers from price gouging and also require all taxpayer-funded COVID-19 research to be recorded in a federal database.
NIH reports that it has halted its clinical trial of hydroxychloroquine after determining the drug has no benefits for COVID-19 patients. "A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19," NIH said.
FDA approved on Thursday burosumab-twza (Crysvita—Ultragenyx Pharmaceutical) injection for the treatment of individuals aged 2 years and older with tumor-induced osteomalacia (TIO). The rare condition is characterized by the development of tumors that cause weakened and softened bones.
Pharmacists now have an additional tool to help them build relationships with physicians and other community partners to improve cardiovascular health for their patients.
The U.S. Court of Appeals for the District of Columbia Circuit has ruled that the Trump administration lacks the legal authority to force drug companies to disclose prices in their television advertisements.
New research indicates that dexamethasone, a widely available steroid, reduced mortality by a third among patients hospitalized with COVID-19. The study has not yet been published or undergone scientific scrutiny, but some experts are optimistic. Former FDA Commissioner Scott Gottlieb called it "a very positive finding" in an interview on CNBC.